Skip to main content

Disclaimer

In the Downloads section, the ‘Prior Submission’ file reflects the most recent measure submission to the former CBE. This file is provided for transparency. For any questions or clarification, please contact the designated measure steward.

Heart Failure - Use of ACE Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) Therapy

CBE ID
0610
1.5 Project
National Voluntary Consensus Standards For Clinically Enriched Administrative Data
Endorsement Status
Endorsement Removed
1.0 New or Maintenance
Maintenance
1.1 Measure Structure
Single Measure
Previous Endorsement Cycle
Full Year 2009
Is Under Review
No
1.6 Measure Description

The percentage of patients aged 18 and older with Heart Failure who are on an ACEI or ARB

Measure Specs
General Information
1.7 Measure Type
Process
1.3 Electronic Clinical Quality Measure (eCQM)
No
1.8 Level of Analysis
Clinician: Group/Practice
Clinician: Individual
Facility
Health Plan
Integrated Delivery System
Other
Population: Community, County or City
Population: Regional and State
1.9 Care Setting
Home Care
Inpatient/Hospital
Outpatient Services
1.20 Types of Data Sources
Claims Data
Electronic Health Data
Electronic Health Records: Electronic Health Records
Instrument-Based Data
Other
1.14 Numerator

Patients with a current fill for an ACEI or ARB

1.15 Denominator

All patients, aged 18 years and older, with a diagnosis of heart failure

Exclusions

Contraindications to an ACEI or ARB, including:
- Hyperpotassemia
- Hypertrophic cardiomyopathy
- Aortic stenosis
- Hypotension
- Pregnancy
- Chronic kidney disease stage 3 and 4
- Chronic kidney disease stage 5 in the absence of dialysis
- Hydralazine after prior ACE-I/ARB use
- 20% increase in creatinine
- Aliskerin
- Multiple myeloma
- Patient data indicating that the member is planning pregnancy
Additional denominator exclusions:
- Heart transplant
- Pulmonary hypertension treatment
- Valve surgery
- Patient or provider feedback indicating allergy, intolerance or contraindication




General exclusions:
- Evidence of metastatic disease or active treatment of malignancy (chemotherapy or radiation therapy) in the last 6 months;
- Patients who have been in a skilled nursing facility in the last 3 months

Most Recent Endorsement Activity
Measure Retired and Endorsement Removed National Voluntary Consensus Standards For Clinically Enriched Administrative Data
Initial Endorsement
Last Updated
Removal Date
Steward Organization
ActiveHealth Management
Steward POC email
[email protected]
Risk Adjustment
No risk adjustment or risk stratification
Use
Planned Use
Public Reporting
Quality Improvement (Internal to the specific organization)
6.1.2 Current or Planned Use(s)
Public Reporting
Quality Improvement (Internal to the specific organization)
6.1.3 Current or Planned Use(s)
Public Reporting
Quality Improvement (Internal to the specific organization)
Public Comments